Abstract
Purpose :
This study aims to evaluate the concentration of riboflavin in corneal tissue and aqueous humor after oral administration of high doses of vitamin B2 ( 400mg/day)
Methods :
This study is prospective, randomized, and comparative study. According to the randomization list, participants were divided into two groups: Group 1: 10 patients with keratoconus who will undergo a daily intake of 400 mg for 10 to 30 days before corneal transplantation. Group 2: 08 patients with keratoconus that will not receive riboflavin. During corneal transplantation, the surgeon was aspirated 0.1 ml of aqueous humor. After the corneal button was removed and preserved in a tube with PBS, masserated, and homogeneized. The both samples were analyzed by Elisa method. Data were collected and presented as mean (standard deviation). The groups were compared using the Wilcoxon rank sum test and p-values less than 0.05 were considered statistically significant. All analyses were performed with Stata v.17 (StataCorp, College Station, Texas).
Results :
The mean (SD) in the group taking oral riboflavin was 27.3 (7.7) years compared to 32.7 (13.4) in the group not taking oral riboflavin (p=0.444). The percentage of males taking oral riboflavin was 61.5% compared to 62.5% in the group not taking the medication (p=0.664).
The median (range) concentration of riboflavin in the cornea in the group taking oral riboflavin was 103.21 (61.45-303.47) µg/g compared to 63.64 (43.30-86.18) µg/g in the group NOT taking oral riboflavin (p=0.004).
The median (range) concentration of riboflavin in the aqueous humor in the group taking oral riboflavin was 6.24 (3.42-66.8) µg/g compared to 3.27 (1.00-6.20) µg/g in the group NOT taking oral riboflavin (p=0.182).
Conclusions :
Our preliminary results demonstrated thathigh doses of oral riboflavin intake reachedhigh concentrations in the aqueous humor and human corneas.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.